Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2023-01-21 AGM Information
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
NOTICE OF 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2023
AGM Information Classification · 98% confidence The document explicitly states it is giving notice of the "convening of meeting" for an "annual meeting" scheduled for 23/02/2023. The agenda items include discussing the auditor's report and re-electing directors, which are standard items for an Annual General Meeting (AGM). Although it mentions the auditor's report (related to AR/10-K), the primary purpose of this filing is the notification and scheduling of the AGM itself. Therefore, the most appropriate classification is AGM Information (AGM-R).
2023-01-21 English
REPORT OF FOREIGN PRIVATE ISSUER
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer. The content primarily announces the upcoming Annual General Meeting (AGM) of shareholders and furnishes related documents such as the Notice and Proxy Statement, Proxy Card, and Voting Instruction Card. The document does not contain financial statements or detailed financial analysis but rather serves as an announcement and provision of meeting materials. The length is 3162 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Proxy Solicitation & Information Statement (PSI), as it includes the proxy materials and voting instructions for the AGM.
2023-01-20 English
Financial results for the nine months ended September 30, 2022
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd. It contains unaudited condensed consolidated financial statements for the nine-month period ended September 30, 2022, along with management's discussion of financial results. Since it provides substantive financial data for an interim period (less than a full fiscal year), it qualifies as an Interim/Quarterly Report (IR) rather than a simple earnings release or regulatory announcement. 9M 2022
2022-11-29 English
Financial results for the nine months ended September 30, 2022
Report Publication Announcement Classification · 98% confidence The document is very short (1808 characters) and explicitly states, "Attached hereto is a report on *291122_Bannerless_isa.pdf*". This structure—a brief filing announcing the availability of an attached or linked report—fits the definition of a Report Publication Announcement (RPA) according to Rule 2 (The 'Menu vs Meal' Rule). It is not the full report itself (like 10-K or IR). The filing is made to the Israel Securities Authority and Tel Aviv Stock Exchange, but the *action* described is the publication of a document, making RPA the most precise classification for this specific notification.
2022-11-29 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains financial results for the nine months ended September 30, 2022, including unaudited condensed consolidated financial statements and a discussion of financial performance. The document is not a full annual report (which would be a Form 20-F), nor is it a quarterly report on Form 10-Q. It is a periodic financial disclosure report for a foreign issuer, typical of Form 6-K filings. The content includes financial data and management commentary but is not a transcript, proxy, or other specific filing type. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-11-29 English
Financial Results for a Period of Six Months Ending June 30, 2022
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd. It contains unaudited condensed consolidated financial statements (Statements of Financial Position and Statements of Comprehensive Income) for the six-month period ended June 30, 2022. Because it provides substantive financial data and analysis for an interim period rather than just an announcement or a certification, it is classified as an Interim/Quarterly Report. H1 2022
2022-08-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.